Clinical Trial

Study of ZG005 in Patients With Advanced Solid Tumors

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-30
notable Enrollment reduced: 100 -> 50 participants 2026-04-30
Trial Details
NCT Number NCT06927687
Lead Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions Advanced Solid Tumor
Enrollment 50 participants
Start Date 2025-06-13
Primary Completion 2027-05 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-29